comparemela.com

Latest Breaking News On - Greg salsburg - Page 4 : comparemela.com

Citius Pharmaceuticals, Inc Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

$33.3 million in cash and cash equivalents as of June 30, 2023; runway through August 2024 CRANFORD, N.J., Aug. 14, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. , a late-stage.

New jerseyUnited statesGreg salsburgLeonard mazurIlanit allenJersey technology business tax certificate transfer programExchange commissionCitius pharmaceuticals incSecurities exchangeDevelopment rd expensesPrnewswire citius pharmaceuticals incCompany nasdaqChief executive officerHalo lido phaseCitius pharmaceuticalsFast track

Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

CRANFORD, N.J., Aug. 10, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. ( Citius or the Company ) (Nasdaq: CTXR), a late-stage biopharmaceuti.

United statesGreg salsburgIlanit allenLeonard mazurSecurities exchangeCitius pharmaceuticals incCompany nasdaqExchange commissionUniversity of texas md anderson cancer centerInfectious diseases society of americaPrnewswire citius pharmaceuticals incChief executive officerLok phaseMino lok phaseInfectious diseases societyCitius pharmaceuticals

Citius Pharmaceuticals, Inc Receives a Complete Response Letter from the U S Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

No clinical efficacy or safety issues raised Citius committed to working toward approval CRANFORD, N.J., July 29, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. today announced that the U.S..

Ilanit allenLeonard mazurGreg salsburgCompany biologics license applicationSecurities exchangeExchange commissionCitius pharmaceuticals incCompany nasdaqPrnewswire citius pharmaceuticals incDrug administrationComplete response letterBiologics license applicationCitius pharmaceuticalsFast trackSecurities actSecurities exchange act

Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes

CRANFORD, N.J., June 26, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. (

Leonard mazurIlanit allenGreg salsburgCitius pharmaceuticals incSecurities exchangeCompany nasdaqExchange commissionCitius pharmaceuticalsFast trackSecurities actSecurities exchange actAnnual report

Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the. | June 20, 2023

Ilanit allenLeonard mazurMyron czuczmanGreg salsburgCitius pharmaceuticals incCompany phaseSecurities exchangeExchange commissionPrnewswire citius pharmaceuticals incDrug administrationPatient reported outcomeHalo lido phaseCentury cures actHemorrhoid qualityLife indexTrial results

vimarsana © 2020. All Rights Reserved.